



THE HONG KONG NEURO-ONCOLOGY SOCIETY



Dear Members of the Hong Kong Neuro-oncology Society (“HKNOS”)

PROFESSIONAL DEVELOPMENT

I am excited to announce that our new website www.hknos.org.hk will be officially launched later this month in time for our **Society's 10th anniversary**.

Abstracts and open-access papers regarding neuro-oncology, especially from our local community can be accessed via this website which will be regularly updated.


Thank you Dr. Michael Lee (PYNEH NS) and Jason Ho (TMH NS) for your unconditional effort!



Molecular Neuropathology is the Future


The new WHO 2021 classification is just around the corner. One of the most interesting features from the “Blue Book” are the updated definitions for WHO 4 gliomas and glioblastoma. This will have a direct impact on how we treat our patients.

Thank you Prof HK Ng (CUHK) for putting Hong Kong on the map and for contributing to this new classification again!



For an excellent review of what's to come, please watch the YouTube talk by Prof Arie Perry (UCSF):

<https://youtu.be/CEY9OqSrLUA>





Please also consider tuning in for the 1st Asian Society Neuro-oncology (ASNO) live webinar available free of charge by registering online at:

<https://asno.wfnos2022.org/asno>

The program (below) will start at

4pm (HKT) Friday, 4th June.



CLINICAL RESEARCH

New Clinical Trial for Patients with Recurrent Glioblastoma

Congratulations to Prof. TC Lam & Dr. Aya Haleli (HKU) (below: right) for recruiting their first subjects for their local clinical trial "TAC-GRed". (ClinicalTrials.gov Identifier: NCT04740190)



Glioblastomas with DNA damage repair deficiencies (dDDR) may be sensitive to the combined effects of carboplatin and talazoparib (PARPi). This phase 2 trial will recruit 33 subjects. The primary endpoint will be PFS at 6 months.

Interested parties: please contact

Ms. Kwan Tel: 2255 5125 / WhatsApp: 2255-5123

HKU Med LKS Faculty of Medicine
Department of Clinical Oncology
香港大學臨床腫瘤學系

誠邀復發膠質母細胞瘤(GBM)患者

參與全新標靶藥物 "TAC-GRed" 臨床研究

本項研究已獲香港大學及醫管局港島西醫院聯網研究倫理委員會批准。這項研究是由香港大學資助，並由林泰忠醫生和瑪麗醫院臨床腫瘤科的研究人員管理下進行。

復發膠質母細胞瘤(GBM)患者 → 篩選評估 (腫瘤基因帶有"dDDR") → 低劑量單次放射治療 → Talazoparib + Carboplatin 聯合治療

研究資料如下:

- Talazoparib是新型的PARP抑制劑，結合Carboplatin以提高抗癌效果。低劑量放射治療提升藥物滲透腦部腫瘤的比例
- 參與者需在研究期內接受口服藥物治療(talazoparib)及每7天注射一次藥物(carboplatin)
- 研究醫生將會定期為參與者進行醫學評估、腫瘤狀況評估、生活質素評估等

如有興趣或查詢，請聯絡香港大學臨床腫瘤學系
(Tel: 2255-5125/WhatsApp: 2255-5123 聯絡滕小姐)

PATIENT ADVOCACY



The Hong Kong Brain Tumor Support Group was established in March 2021 and is the only group of this nature dedicated to those with brain tumors and their caregivers in the city.



Under the motto “Where Hope Matters”, the group aims to bring together patients and their caregivers fighting against brain tumors to offer moral and practical support.

The group is currently looking to see if members of our Society would like to hold talks in their area of expertise to help better understand how to handle this illness.

Interested parties can contact them at: hkbraintumorpatient@gmail.com


or visit their Facebook page: <https://www.facebook.com/HKBrainTumourPatientGroup/>

PARTING WORDS

As we reach the conclusion of the 4th wave of the COVID-19 pandemic, I continue to wish you all good health!

Yours,

Peter Woo
President, HKNOS



In Support of "Go Gray in May: Brain Tumor Awareness Month".
A local Hong Kong patient sports her manicure with the “Gray Ribbon of Hope”